Skip to main content
JW PHARMACEUTICAL logo

JW PHARMACEUTICAL — Investor Relations & Filings

Ticker · 001060 ISIN · KR7001060003 KO Manufacturing
Open in API
Filings indexed 310 across all filing types
Latest filing 2025-03-11 Proxy Solicitation & In…
Country KR South Korea
Listing KO 001060

About JW PHARMACEUTICAL

https://www.jw-pharma.co.kr/pharma/en/m…

JW Pharmaceutical is a company focused on the research, development, and commercialization of pharmaceutical products. It provides a broad portfolio of therapeutic drugs, including specialty medicines and over-the-counter (OTC) solutions. Key product areas include nutritional infusions (Combiflex®, Winuf®), treatments for neutropenia (Neutrogin®), and cardiovascular medicines (Livalo®). Its consumer healthcare offerings feature the Hi-mom® brand of advanced wound care products. The company emphasizes innovation, advancing a pipeline of new drugs targeting oncology and immune diseases. This research is driven by proprietary technology platforms and includes candidates such as the gout treatment Epaminurad.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for JW Pharmaceutical. It contains the agenda for the upcoming Annual General Meeting (AGM), including items for approval such as financial statements, director appointments, and amendments to the articles of incorporation. It also provides proxy solicitation information and details on electronic voting. This document is a standard proxy statement/notice sent to shareholders to inform them of the meeting and request their votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-11 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains details about the meeting agenda, board proposals, financial summaries, and voting procedures. While it contains financial information, it is specifically a proxy solicitation document, which falls under the 'Proxy Solicitation & Information Statement' category.
2025-03-11 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical regarding the acquisition of shares in another company (Euvipharm JSC). It details the acquisition amount, purpose, and board approval, which constitutes a corporate action related to capital structure and investment. In the context of Korean regulatory filings (DART), this is a 'Major Disclosure' (주요사항보고서) regarding the acquisition of shares in another corporation, which falls under the 'Regulatory Filings' (RNS) category as it is a specific corporate announcement that does not fit into the other specialized categories like M&A (which usually implies a merger or takeover of the entity itself) or Share Issue (which is about the company's own stock).
2025-03-06 Korean
유상증자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from JW Pharmaceutical regarding a capital increase (paid-in capital increase) for its subsidiary, Euvipharm JSC. It details the number of new shares, the purpose of the funds (facility and debt repayment), and the method of issuance. This falls under the category of capital and financing updates, specifically related to share issuance and capital structure changes for a subsidiary.
2025-03-06 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from JW Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the dividend record date, and the upcoming shareholder meeting date. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2025-02-11 Korean
공정거래자율준수프로그램운영현황(안내공시)
Governance Information Classification · 100% confidence The document is a regulatory filing from JW Pharmaceutical detailing their 'Compliance Program' (CP) operational status and future plans. It covers internal governance, training, monitoring, and disciplinary actions related to fair trade practices. This type of disclosure is a standard regulatory announcement in the Korean market (KIND system) regarding corporate governance and compliance, which falls under the 'Regulatory Filings' category as it does not fit into specific financial or shareholder-event categories.
2025-02-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.